DEF: Avanos Medical Outlines 2026 Annual Meeting Proposals

Avanos Medical, Inc. announces its 2026 Annual Meeting of Stockholders to address director elections, auditor ratification, executive compensation, and an amendment to its long-term incentive plan.

Summary

• The 2026 Annual Meeting of Stockholders will be held on April 21, 2026, to vote on the election of eight directors, ratification of Deloitte & Touche LLP as independent auditors, an advisory vote on named executive officer compensation, and an amendment to the 2021 Long Term Incentive Plan.
• The proposed amendment to the 2021 Long Term Incentive Plan will allow for the issuance of equity awards to outside directors without increasing the total shares reserved or causing stockholder dilution.
• For the fiscal year ended December 31, 2025, Avanos Medical reported net sales of $701.2 million, adjusted EBITDA of $86.8 million, and adjusted diluted EPS of $0.94.
• Cash on hand at December 31, 2025, was $89.8 million.
• The 2025 annual cash incentive program for named executive officers resulted in an aggregate payout of 139%, driven by adjusted net sales of $656.8 million (173% payout) and adjusted EBITDA of $107.4 million (124% payout), alongside 100% payout for strategic initiatives.
• The 2025 portion of the 2025 Performance-Based Restricted Share Units (PRSUs) is projected to vest at 139.5% of target, based on free cash flow of $79 million (97.0% payout) and year-over-year Return on Invested Capital (ROIC) of 6.2% (42.5% payout).
• The 2025 portion of the 2024 PRSUs is projected to vest at 82.7% of target, and the 2025 portion of the 2023 PRSUs vested at 74.3% of target, contributing to an aggregate vesting of 75.8% of target for the full three-year period of the 2023 PRSUs.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a generally positive and routine proxy statement, highlighting strong operational performance and governance, despite a reported net loss. The proactive sustainability efforts and robust executive compensation structure are favorable, though the high CEO pay ratio might warrant attention.

Positives

• The company maintains strong corporate governance practices, including separate Chairman and CEO roles, a diverse and independent board, and active stockholder engagement.
• Significant progress was made in sustainability efforts in 2025, with Scope 2 greenhouse gas (GHG) emissions declining by 61%, total GHG emissions (Scope 1 and 2) reduced by 54%, electricity consumption down 60%, total waste output decreased by 48%, and water demand decreased by 73%.
• The CEO noted 'meaningful progress on our strategic priorities,' 'healthy organic growth,' and 'tariff mitigation efforts on track,' indicating positive operational momentum.
• The executive compensation program is strongly aligned with pay-for-performance, with a majority of 2025 direct annual compensation being performance-based and equity-based.
• The reintroduction of stock options into the long-term incentive mix for executives directly aligns their interests with stockholder value creation.
• The 2025 annual cash incentive program achieved an aggregate payout of 139% for named executive officers, demonstrating strong performance against internal targets.
• The 2025 portion of the 2025 PRSUs is projected to vest at 139.5% of target, reflecting robust performance against its specific free cash flow and ROIC goals for the year.
• The company reported a low OSHA recordable incident rate of 0.06 per 100 employees in 2025, highlighting a strong commitment to employee health and safety.

Negatives

• Despite positive adjusted metrics, the company reported a net (loss) income of $(72.9) million for 2025, although this was an improvement from $(386.3) million in 2024.
• Adjusted EBITDA decreased from $107.6 million in 2024 to $86.8 million in 2025.
• Adjusted diluted EPS decreased from $1.35 in 2024 to $0.94 in 2025.
• The 2025 performance for the 2024 PRSUs (82.7% of target) and 2023 PRSUs (74.3% of target) showed payouts below target for the respective year's portion, indicating some variability in achieving long-term performance goals across different grant years.
• The ratio of CEO compensation to median employee compensation was high at 1,480:1 for 2025.

Risks

• The Audit Committee oversees risks related to internal controls, cybersecurity, financial statement integrity, and fraud.
• The Compensation Committee reviews the risk profile of compensation policies and practices to ensure they do not encourage excessive risk-taking.
• The Compliance Committee monitors risks related to various compliance matters, including Code of Conduct, consumer protection, ethics, anti-bribery laws, and regulatory adherence.
• The Governance Committee monitors risks relating to corporate governance matters.
• Senior management identifies and monitors key enterprise-wide and business unit risks, including hedging, foreign currency, country risks, product liability, property and casualty risks, and supplier and customer risks.

Future Outlook

The CEO anticipates healthy organic growth for 2026, with tariff mitigation efforts on track and cost management initiatives beginning to show impact. The company aims to continue delivering clinically superior breakthrough medical device solutions globally.

Management Comments

• I am pleased with our fourth quarter results and full-year results, which demonstrate meaningful progress on our strategic priorities. Our organic growth remains healthy and positions us well for 2026. Our tariff mitigation efforts are on track, and we're beginning to see the impact of our cost management initiatives. I'm proud of our team's focus and commitment.

Industry Context

StockSavvy.ai notes that Avanos Medical operates in the competitive medical technology sector, focusing on specialized niches like nutrition systems and non-opioid pain management. The company's emphasis on sustainability and corporate citizenship, including efforts to reduce opioid abuse, aligns with broader industry trends towards ESG (Environmental, Social, and Governance) factors and patient-centric care. The reintroduction of stock options in executive compensation reflects a common strategy to align management incentives with long-term shareholder value in a capital-intensive industry.

Comparison to Industry Standards

• The company's executive compensation peer group includes medical technology companies such as Accuray Incorporated, AngioDynamics, Inc., CONMED Corporation, ConvaTec Group Plc, Globus Medical Inc., ICU Medical, Inc., Insulet Corporation, Integer Holdings Corporation, Integra Lifesciences Holding, Lantheus Holdings, Inc., Masimo Corporation, Merit Medical Systems, Inc., Orthofix Medical, Bioventus Inc., and AtriCure, Inc.
• Avanos Medical aims to set base salaries and target annual incentive compensation payout opportunities at or above the 50th percentile of its peer group to remain competitive in attracting and retaining executive talent.
• The company's sustainability metrics, such as a 61% reduction in Scope 2 GHG emissions and a 73% decrease in water demand in 2025, demonstrate strong performance in environmental stewardship, potentially exceeding some industry averages.
• The OSHA recordable incident rate of 0.06 per 100 employees in 2025 is a very low figure, suggesting excellent workplace safety performance compared to general manufacturing or healthcare industry benchmarks.

Management Changes

Corporate Governance

Stakeholder Impact

• Shareholders will vote on key governance matters, including director elections and executive compensation, and the proposed amendment to the 2021 Long Term Incentive Plan aims to align outside directors' interests with shareholders without dilution.
• Employees benefit from the company's commitment to a fair and inclusive workplace, health and safety initiatives (evidenced by a low 0.06 OSHA recordable incident rate in 2025), and engagement/retention programs.
• Customers and patients are impacted by the company's mission to deliver clinically superior breakthrough medical device solutions, particularly in specialty nutrition and non-opioid pain management.
• Suppliers are expected to mirror the company's integrity, focusing on quality, service, fair dealing, and responsible corporate citizenship.
• Executives' compensation is tied to performance, with a mix of base salary, annual cash incentives, and long-term equity incentives, designed to attract and retain key talent and align with company performance.

Next Steps

• Stockholders will vote on director elections, auditor ratification, executive compensation, and the 2021 Long Term Incentive Plan amendment at the Annual Meeting on April 21, 2026.
• The annual grant of restricted share units to Outside Directors will occur on April 22, 2026, subject to stockholder approval of Proposal 4.
• A one-time grant of 5,168 restricted share units will be made to acting Outside Directors (excluding Messrs. Burke and Cunniff) on April 22, 2026, to account for the change in annual grant date.
• Prorated bonuses for 2025 for certain former executives (Mr. Greiner, Mr. Holbrook, Ms. James) are scheduled to be paid in March 2026.
• The 2024 PRSUs will vest on March 6, 2027, based on combined performance through 2026.
• The 2025 PRSUs will vest on March 7, 2028, based on combined performance through 2027.
• The Board will continue its ongoing review of governance practices, regulatory requirements, and issues raised by stockholders.
• The Compensation Committee will conduct annual reviews of executive officer compensation objectives, policies, and the executive compensation peer group.

Key Dates

Recommendation

The filing is a routine proxy statement for an annual meeting, primarily focused on corporate governance, executive compensation, and director elections. While 2025 financial highlights show positive adjusted metrics and strong operational performance, the reported net loss and high CEO pay ratio are points of consideration. The company demonstrates solid ESG practices and a commitment to aligning executive incentives with long-term value. However, without new material financial guidance or strategic shifts, the filing does not present information that would typically warrant a 'buy' or 'sell' recommendation for a seasoned investor; a 'hold' position is appropriate to observe continued execution of strategic priorities and future financial results.

Keywords

Medical Technology, Corporate Governance, Executive Compensation, SEC Filing, Proxy Statement, Financial Performance, Sustainability, Risk Management, Board of Directors, Shareholder Meeting, Avanos Medical, Medical Devices, ESG